



U. S. Department of Justice
Drug Enforcement Administration
8701 Morrisette Drive
Springfield, Virginia 22152

www.dea.gov

Michael Baxter
Vice President, Government Affairs
American Pharmacists Association
mbaxter@aphanet.org

Dear Mr. Baxter:

This is in response to your letter dated March 3, 2025, addressed to Derek S. Maltz, former Acting Administrator, Drug Enforcement Administration (DEA). Your letter was forwarded to the DEA Diversion Control Division on May 7, 2025, for response. In addition to the American Pharmacists Association, your letter was submitted to DEA on behalf of the American Association of Colleges of Pharmacy, American Association of Psychiatric Pharmacists, American College of Clinical Pharmacy, American Society of Consultant Pharmacists, American Society of Health-System Pharmacists, Colorado Pharmacists Society, Iowa Pharmacy Association, National Alliance of State Pharmacy Associations, National Association of Chain Drug Stores, National Community Pharmacists Association, Nevada Pharmacy Alliance, North Dakota Pharmacists Association, and Oregon State Pharmacy Association. DEA apologizes for the delay in responding to you and appreciates the opportunity to address your concerns. We are sending an identical response to the associations listed above.

In your letter, you requested, in part, that the DEA update its online registration process and the Mid-Level Practitioners Authorization by State (MLPAS) table to reflect recent changes in state laws and regulations that explicitly grant pharmacists prescriptive authority for controlled substances. Further, you provided information about several states, specifically Colorado, Iowa, Nevada, North Dakota, and Oregon, that you stated have enacted legislation or promulgated regulations that authorize pharmacists to prescribe controlled substances. You requested that DEA update the MLPAS table accordingly.

As part of DEA's ongoing effort to ensure our resources reflect the most up-to-date information available, the MLPAS table has been removed from the DEA Diversion Control Division website and is in the process of being reviewed. During this review, DEA will consider the information you provided about the legislation and regulations in Colorado, Iowa, Nevada, North Dakota, and Oregon. Once DEA has completed its review, the DEA Form 224, Application for Registration, will be updated appropriately.

I trust this response adequately addresses your inquiry. For information regarding DEA's Diversion Control Division, please visit <https://DEAdiversion.usdoj.gov>. If you have any additional questions on this issue, please contact the Diversion Control Division's Policy Section at (571) 362-3260.

Sincerely,

Thomas W. Prevoznik
Assistant Administrator
Diversion Control Division

cc: American Association of Colleges of Pharmacy
American Association of Psychiatric Pharmacists
American College of Clinical Pharmacy
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Colorado Pharmacists Society
Iowa Pharmacy Association
National Alliance of State Pharmacy Associations
National Association of Chain Drug Stores
National Community Pharmacists Association
Nevada Pharmacy Alliance
North Dakota Pharmacists Association
Oregon State Pharmacy Association